Gensight Biologics S.a annual shareholders’ equity
2020
2021
2022
2023
2024
2025
Gensight Biologics S.a Shareholders’ Equity Growth & History (SIGHT)
Gensight Biologics S.a's shareholders’ equity was −€24.9M for fiscal 2025.
View full Gensight Biologics S.a company overviewGensight Biologics S.a annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −€24.9M | €2.0M | — |
| 2024 | 2024-12-31 | −€26.9M | €3.8M | — |
| 2023 | 2023-12-31 | −€30.7M | −€15.4M | — |
| 2022 | 2022-12-31 | −€15.3M | −€31.3M | — |
| 2021 | 2021-12-31 | €16.0M | €4.2M | +36.09% |
| 2020 | 2020-12-31 | €11.7M | — | — |
Gensight Biologics S.a quarterly shareholders’ equity
Q4.24
Q4.25
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | −€24.9M | €2.0M | — |
| Q4 2024 | 2024-12-31 | −€26.9M | — | — |
Gensight Biologics S.a shareholders’ equity trends
Over the last five fiscal years, Gensight Biologics S.a's shareholders’ equity decreased from €11.7M to −€24.9M, a change of −€36.7M. The latest reported quarter, Q4 2025, shows −€24.9M.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company official filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gensight Biologics S.a source filings ↗Community posts
GenSight advances LUMEVOQ manufacturing transfer to Catalent
GenSight ($SIGHT) said an engineering batch of GS010/LUMEVOQ at Catalent was produced as planned, with viral genome concentration meeting target specifications. Preparations have begun for a GMP-standard batch to supply special-access progr ...